Lyell Immunopharma (LYEL) Return on Equity (2020 - 2026)

Lyell Immunopharma's Return on Equity history runs 7 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Lyell Immunopharma, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2023 to a low of 0.01% in Q2 2025.
• A 5-year average of 0.01% and a median of 0.0% in 2024 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 0 bps in 2022 and fell as far as 1 bps in 2022.
• Lyell Immunopharma's Return on Equity stood at 0.0% in 2022, then tumbled by 52 bps to 0.0% in 2023, then tumbled by 122 bps to 0.01% in 2024, then decreased by 21 bps to 0.01% in 2025, then retreated by 6 bps to 0.01% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.01%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison